Byrd Scott

All filings by Byrd Scott on record concern Acacia Pharma Group. Over a trading history stretching from 30 June 2021 to 29 December 2021, the count stands at 3 filings.

No open-market sale appears; the market trades are 3 purchases worth €19k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2022, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €6,433. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

On 7 January 2022 came the latest disclosure, an open-market purchase for €6,506 in Acacia Pharma Group. Between a trade and the moment it shows up on FSMA, the median delay is 9 days. The legal deadline for notifying a trade is three business days (MAR article 19). This summary is built from FSMA disclosures alone and does not predict where the share price will go.